Medical network - on April 24, in our country, the skin is a common disease, the incidence is higher, the state, the former deputy minister of health, the Chinese medical doctor association, honorary President of YanDaKui mentioned that by 2014 about 420 million people worldwide suffer from skin diseases, China has nearly 150 million people. 

 

Due to the modern life rhythm speeding up and the deterioration of the environment, the incidence of skin disease increased year by year in our country, skin disease drug market is also growing. M, according to data from the network in the first half of 2013-2016 skin medicine retail market performance improved steadily, and antifungal drugs are the most popular, hormone drugs significantly, which drug firms are skin medicine retail market dominance? Together we look down. 

 

Skin medicine retail market is good, sales climbed steadily 

 

Dermatology drug use is one of the key category of medicine retail market, sales keep rising steadily in recent years. M network statistics, nearly three years of sales rising, but growth slowed. Skin disease in the first half of 2016 4.6% of the medicines retail market, bigger development space. 

 

 

 

Growth is obvious antifungal drugs is most popular, other performance-enhancing drugs 

 

At present, the skin diseases are infectious skin disease, skin disease, autoimmune skin disease allergic or immune correlation, etc. According to different risk factors, the general dermatology drug use can be divided into anti fungi, hormonal, antibacterial, antiviral and so on. Among them, the antifungal sales account for larger classes and other performance-enhancing drugs, combined market share of 44.4% in the first half of 2016. 

 

 

 

M network statistics show that in dermatology medicine retail market, 2013-2016 in the first half of antifungal drugs firmly in the first place, the market share of more than 20%. Hormonal drugs in second place, and market share increase year by year, 18.6% in the first half of 2016. Among them, the CRC san-jiu furoic acid mo betamethasone gel growth is more apparent, the market share is only 1.2% in 2013, the first half of 2016 to 2.1%. 

 

Hormonal skin disease medication has good antiallergic and anti-inflammatory effects, and the rapid effect, obvious effect, short-term drugs are often used to relieve symptoms. The drug has obvious seasonal, every summer is the peak sales. Pharmacy can be skin to identify joint manufacturer in advance to the clerk and rational drug use in the training, and make relevant display and propaganda work, let the consumer can gain a better understanding of skin diseases, thus promote the sales of the drugs. 

 

 

Ointments accounts for half of dermatology drug market, gels outlook 

 

Unlike most disease medication, topical formulations of skin disease medication dominance, and minimal oral dosage forms of the market share, mainly is the topical formulations direct effects on the skin, is easy to use, quick effect and low side effect, etc, by the patients of all ages. 

 

Topical formulations including soft paste, liquid, solution, gels for external use only, including sales accounted for the biggest ointments. M network statistics show that in the first half of 2013-2016, soft paste market share of more than 50%, the market position. External use liquid ranked second, market share steadily upward, above 10% in the first half of 2016. 

 

It is important to note that the gels, as a new type of external preparation, is easy to use, good biocompatibility, high bioavailability, fast absorption, homogeneous structure etc, sales rose steadily, the market share of 6.2% in the first half of 2016, better growth. 

 

 

 

Three big companies led by skin medicine retail market 

 

M network statistics show that in dermatology drug retail market, in the first half of 2013-2016 are the best-selling TOP3 manufacturer of xi 'an yeung sum pharmaceutical, dian hong pharmaceutical co., China resources san-jiu pharmaceutical co., here is a brief scan of its market performance. 

 

NO. 1 xi 'an yeung sum pharmaceutical 

 

In dermatology medicine retail market, xi 'an yeung sum strong pharmaceutical status, ranks first in recent years, the market share of nearly 10% in the first half of 2016. Dermatology drug use is one of the major areas of xi 'an yeung sum pharmaceutical sales, main antifungal drugs, long-term investment in advertising and brand strategy to stabilize the its status in the retail market, gold daktarin, daktarin, perry pine and other well-known brand is widely known and accepted over-the-counter medicines. Gold daktarin (ketone health zun cream) and daktarin (miconazole nitrate cream) as main product, the market performance is good, keep steady growth in sales, sales in the first half of 2013-2016 rankings can enter the dermatology drug use among the top 10 brands, market position. 

 

 

 

In dermatology medicine retail market, dian hong pharmaceutical well, the first half of 2013-2016 were came second in the market, its main products for the extract epurated from lotion (compound ketone health zun lotion). Extract epurated from lotion for resistance to fungal skin disease, in the first half of 2016 sales accounted for 4.8% of skin diseases medicine retail market, is a skin disease medicine retail market's best-selling products. In addition, yunnan hong pharmaceutical's skin disease medication and compound ketone health zun cream vitamin E cream, furoic acid, urea, loperamide cream, hydrochloric acid, than naphthalene creams and other products, including compound ketone health zun cream has good performance, in the first half of 2016 by leaps skin medicine top 10 brands in the retail market, the market share of 1.5%. 

 

 

 

NO. 3 CRC san-jiu pharmaceutical industry 

 

In the first half of 2013-2016 China resources pharmaceutical sales account for lump-sum than keep the top three in the dermatology medicine retail market, and a small rise. Huarun san-jiu pharmaceutical main core business is OTC and prescription drugs, Chinese traditional medicine its core OTC products in dermatology drug market occupy a higher market share. Its 999 dermatitis flat (compound dexamethasone acetate cream, furoic acid betamethasone gel) in the domestic pharmaceutical market have higher visibility. In the first half of 2016 compound dexamethasone acetate cream and furoic acid mo betamethasone gel market share of 2.5%, 2.1% respectively, both can enter the top ten brands of skin diseases medicine retail market. 

 

 

 

Comprehensive above, because our country dermatosis patients increased year by year, skin disease drug market scale will continue to maintain steady growth. With the influx of foreign companies, the new medical reform policy implementation, there will be more prescription drugs into the retail terminal, makes the retail market is more competitive and skin disease in our country medicine retail market will be further expanded. 

 

Note: in this paper, according to the China retail pharmacies m network terminal competition 22 city sample data (such as no special instructions, the article 22 cities are aggregate data)